| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.09 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.09 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.1 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |